Moreover, the market is further influenced by technological advancements to develop solutions to use across wide range of applications, hence providing lucrative opportunities for the market growth. However, lack of awareness of such technologies especially in emerging economies is expected to hinder the market growth.
According to Centers of Disease Control and Prevention States, approximately each year 900,000 people could be affected (1or 2 per 1,000) in the U.S. Also, CDC states that approximately 60,000 -100,000 Americans die due to venous thromboembolism. Also, some 10-30% of the people will die within the initial one month of diagnosis.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32628
Also, part from the disease burden, VTE also can lead to economic burden. Prolonged hospital stays and follow up care including recurrent VTE, can be heavy on pockets. For instance, In the U.S., the associated cost with the diagnosis and treatment costs US $ 15.5 billion per year, while in the U.K. VTE costs the National Health Services €640 million per year.
Also, the pacific regions are expected to witness the burden associated with the VTE, which is estimated to be at US $1.72 billion a year. Also, when loss of well-being such as disability and premature death are included, the can annual cost can rise to US $ 19.99 billion (Source: International Society on Thrombosis and Haemostasis).
Thus, high number of cases and economic burden associated with the VTE demands the enhance care which can improve the blood flow and mobility among the patients. Factors such as these are expected to drive the sales of the muscle pump activators.
Apart from expansion of use in kidney transplantation, the muscle pump activators proves beneficial in wound care therapy – treating chronic venous ulcers, reducing leg swelling (edema), reduces heavy legs and pain sensation, and also is effective in treating restless legs and night cramps. Thus, expanding use of the muscle pump activators in various indications are expected to drive the growth of the market during the forecast period of 2021—2031.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32628
Patients using these devices following kidney transplantation experienced shorter hospitals stays and reduced surgical site infection by 60%. Such positive results will help increase the adoption of muscle pump activators for innovative devices among hospitals and specialty clinics for improving quality for life specifically from the patients suffering from end stage renal disease. Additionally, well established distribution network (leading to better product availability) will positively drive the sales of muscle pump activators in the U.S. and Canada Market.
Muscle pump activators Mimicking body’s signals, these devices gently stimulates the common peroneal nerve, by activating the calf and muscle foot pumps, resulting into the improved blood circulation flow in the deep veins in the calf muscle which allows the complete mobility.
The ongoing advancements in research and development in this space, has allowed the use of these devices for use in other indications such as post-operative care after kidney transplantation. Majorly, these players are aiming to expand their presence across by via introducing new products and approvals and stgrenthing their existing, as well creating new distribution network. This strategic move will enable these players to expand their product offerings in the muscle pump activator market
For instance, in October 2019, Sky Medical Technology Ltd (U.K.) has received U.S. FDA approval for its muscle pump activator- geko, wearable device. These device will provide stimulation to calf muscles to prevent the risk of venous thromboembolism for non-surgical patients who are at risk of developing VTE.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32628